ACIP Postpones Vote on Delaying Newborn Hepatitis B Vaccine

The Advisory Committee on Immunization Practices (ACIP) postponed a planned vote on delaying the first hepatitis B vaccine dose for certain newborns, creating uncertainty over the childhood immunization schedule. The committee considered whether infants born to mothers who tested negative for hepatitis B could safely defer vaccination for at least one month.

Eleven ACIP members voted to table the decision indefinitely, citing unresolved questions on safety, effectiveness, and timing, while one member opposed tabling. Some panelists raised concerns about prenatal testing gaps and the risks of infants not receiving timely protection. The hepatitis B vaccine, recommended within 24 hours of birth and over 90% effective, prevents long-term liver disease, including cirrhosis and cancer.

Manufacturers Sanofi and Merck urged ACIP to maintain current guidance. With the vote postponed, it remains unclear when the committee will revisit the recommendation; a tentative meeting is scheduled for October.

21-09-2025